Scipher Medicine expands its global presence, bringing precision medicine to Latin America through an alliance with Grupo Amarey
PrismRA is the first molecular test of its kind that provides objective data to help healthcare professionals select the most effective biologic therapy for each RA patient, improving clinical outcomes and reducing unnecessary and ineffective treatments.
'Our mission at Scipher Medicine is to eliminate the trial-and-error approach in the treatment of autoimmune diseases by providing physicians with actionable, data-driven insights,' said Reg Seeto, CEO of Scipher Medicine. 'Expanding into Latin America, starting with Colombia through our partnership with Grupo Amarey, is a key step in our global strategy. Grupo Amarey's deep understanding of the local healthcare system and its commitment to innovation make them the ideal partner to bring PrismRA to the patients who can benefit most.'
With its extensive experience and strong presence in the healthcare market in Colombia, Grupo Amarey is in a privileged position to facilitate the adoption and integration of PrismRA into clinical practice.
'We are excited to partner with Scipher Medicine to introduce PrismRA in Colombia,' said Dr. Manuel Camacho, General Manager of Grupo Amarey. 'Precision medicine holds tremendous potential to improve patient care, especially in complex diseases like rheumatoid arthritis. This collaboration reinforces our commitment to bringing cutting-edge diagnostic tools and new therapies to patients and healthcare professionals in Colombia, promoting more personalized and effective treatment decisions.'
The terms of the agreement were not disclosed. This alliance highlights Scipher Medicine's commitment to advancing precision medicine globally, as well as Grupo Amarey's leadership in strengthening healthcare services in Latin America.
About Scipher Medicine:
Scipher Medicine drives the probability of success at each stage of drug development, from discovery to commercialization, by combining artificial intelligence with network biology and proprietary data, through its SPECTRA Rx and Dx platforms. Scipher has the industry's largest non-oncology clinico-genomic data asset and biobank, along with electronic medical records (EMR) data for more than 3 million rheumatology patients. For more information, visit: www.sciphermedicine.com.
About PrismRA:
PrismRA is a revolutionary blood test bringing precision medicine to the treatment of rheumatoid arthritis, which affects 20 million patients worldwide. From a routine blood draw, the PrismRA test analyzes the patient's individual molecular signature, helping to identify those who are unlikely to adequately respond to TNFi therapy, the world's best-selling drug class, so that alternative effective therapies can be prescribed, avoiding unnecessary dose escalations or drug cycles. Physicians now have objective data to inform therapeutic decision-making and give patients the best chance to achieve treatment targets and improve clinical outcomes. For more information, visit: PrismRA.com.
About Grupo Amarey
Grupo Amarey is a leading company in the representation and distribution of technologies, solutions, and services for the healthcare sector in Colombia, Panama, and Costa Rica. Through partnerships with high-quality international brands, Grupo Amarey brings innovation in areas such as diagnostics, medical devices, biotechnology, laboratory, specialized surgical technologies, and hospital supplies, contributing to improved healthcare delivery and patient quality of life in the region. For more information, visit: www.grupoamarey.com.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
2 hours ago
- Business Wire
Sensorion Announces an Increase in Resources Allocated to the Liquidity Contract with Kepler Cheuvreux
MONTPELLIER, France--(BUSINESS WIRE)--Regulatory News: Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company specializing in the development of novel therapies to restore, treat and prevent hearing loss disorders, today announces an increase in resources allocated to the liquidity contract entrusted to Kepler Cheuvreux. On 15 December 2017 Sensorion entered into a Liquidity Contract with Kepler Cheuvreux, modified by amendments dated 7 December 2018 and 15 July 2022 (the " Contract"). This Contract aims to promote the liquidity of the Shares of Sensorion on Euronext Paris. On 14 August 2025, in accordance with Article 4 of AMF Decision No. 2021-01 of 22 June 2021 renewing the establishment of liquidity contracts on equity securities as an accepted market practice, Sensorion increased the resources allocated to the liquidity contract by €60,000. Following this increase in resources, as of 14 August 2025, the following assets appear on the liquidity account: - 206,211 Sensorion Ordinary Shares - €66,965.21 About Sensorion Sensorion is a pioneering clinical-stage biotech company, which specializes in the development of novel therapies to restore, treat, and prevent hearing loss disorders, a significant global unmet medical need. Sensorion has built a unique R&D technology platform to expand its understanding of the pathophysiology and etiology of inner ear related diseases, enabling it to select the best targets and mechanisms of action for drug candidates. It has two gene therapy programs aimed at correcting hereditary monogenic forms of deafness, developed in the framework of its broad strategic collaboration focused on the genetics of hearing with the Institut Pasteur. SENS-501 (OTOF-GT) currently being developed in a Phase 1/2 clinical trial, targets deafness caused by mutations of the gene encoding for otoferlin and GJB2-GT targets hearing loss related to mutations in GJB2 gene to potentially address important hearing loss segments in adults and children. The Company is also working on the identification of biomarkers to improve diagnosis of these underserved illnesses. Sensorion's portfolio also comprises programs of a clinical-stage small molecule, SENS-401 (Arazasetron), for the treatment and prevention of hearing loss disorders. Sensorion's small molecule progresses in a Phase 2 proof of concept clinical study of SENS-401 in Cisplatin-Induced Ototoxicity (CIO) for the preservation of residual hearing. Sensorion, with partner Cochlear Limited, completed in 2024 a Phase 2a study of SENS-401 for the residual hearing preservation in patients scheduled for cochlear implantation. A Phase 2 study of SENS-401 was also completed in Sudden Sensorineural Hearing Loss (SSNHL) in January 2022. Disclaimer This press release contains certain forward-looking statements concerning Sensorion and its business. Such forward looking statements are based on assumptions that Sensorion considers to be reasonable. However, there can be no assurance that such forward-looking statements will be verified, which statements are subject to numerous risks, including the risks set forth in the 2024 full year report published on March 14, 2025, and available on our website and to the development of economic conditions, financial markets and the markets in which Sensorion operates. The forward-looking statements contained in this press release are also subject to risks not yet known to Sensorion or not currently considered material by Sensorion. The occurrence of all or part of such risks could cause actual results, financial conditions, performance or achievements of Sensorion to be materially different from such forward-looking statements. This press release and the information that it contains do not constitute an offer to sell or subscribe for, or a solicitation of an offer to purchase or subscribe for, Sensorion shares in any country. The communication of this press release in certain countries may constitute a violation of local laws and regulations. Any recipient of this press release must inform oneself of any such local restrictions and comply therewith.
Business Wire
6 hours ago
- Business Wire
ESS Schedules Second Quarter 2025 Financial Results Conference Call
WILSONVILLE, Ore.--(BUSINESS WIRE)--ESS Tech, Inc. (ESS) (NYSE: GWH), a leading manufacturer of iron flow long-duration energy storage (LDES) systems for commercial- and utility-scale applications, today announced that it will hold a conference call on Thursday, August 14, 2025 at 5:00 p.m. EDT to discuss financial results for its second quarter 2025 ended June 30, 2025. The news release announcing the second quarter 2025 financial results will be disseminated on August 14, 2025 after the market closes. Interested parties may join the conference call beginning at 5:00 p.m. EDT on Thursday, August 14, 2025 via telephone by calling (833) 470-1428 in the U.S., or for international callers, by calling +1 (404) 975-4839 and entering conference ID 271308. A telephone replay will be available until August 21, 2025, by dialing (866) 813-9403 in the U.S., or for international callers, +1 (929) 458-6194 with conference ID 482125. A live webcast of the conference call will be available on ESS' Investor Relations website at A replay of the call will be available via the web at About ESS Tech, Inc. At ESS (NYSE: GWH), we deliver safe, sustainable, long-duration energy storage to ensure energy abundance and security. As energy demand continues to grow, our solutions provide essential reliability and resilience to people, communities, and businesses in the United States and throughout the world. Our technology uses earth-abundant iron, salt and water to deliver environmentally safe solutions capable of providing 10+ hours of flexible energy capacity for commercial and utility-scale energy storage applications. Established in 2011, ESS enables project developers, independent power producers, utilities and other large energy users to deploy reliable, sustainable long-duration energy storage solutions. For more information, visit
Business Upturn
6 hours ago
- Business Upturn
Liquid I.V. Debuts Innovative New Sugar-Free Hydration Multiplier in Canada
TORONTO, Aug. 14, 2025 (GLOBE NEWSWIRE) — Today, Liquid I.V., the number one selling powdered hydration brand in Canada1 announced the expansion of their product portfolio with the launch of the new Sugar-Free Hydration Multiplier. Available in the delicious and refreshing White Peach flavour, this launch marks Liquid I.V.'s most significant innovation in the market to date and is the brand's first sugar-free offering for Canadians. 'Sugar-free marks a bold step forward for Liquid I.V., cementing our place not only as leaders but innovators of hydration solutions,' said Anusha Babbar, Senior Vice President of International, Unilever Wellbeing. 'Canadians have shown great love to Liquid I.V. these past two years in market, so we're thrilled to be expanding our Canadian offering in the wellness category to meet their demands for a sugar-free option.' Liquid I.V. entered Canada in 2023, marking its first expansion beyond the U.S., and quickly established itself as a leading provider of powdered hydration. Yet, fans of the electrolyte beverage have been vocal about the need for a sugar-free option to meet their lifestyle needs. Today, Liquid I.V. responds to the demand with a first-of-its-kind formula that is scientifically formulated to restore electrolyte imbalances that occur through performance, heat, travel and adventure, without the sugar. 'Sugar is often used as a key ingredient in electrolyte beverages for hydration support. We clinically tested countless sugar-free formulations to ensure that we weren't just ticking a box, but creating a formula backed by science that truly supported functional hydration,' said Lori Lauersen, Senior Vice President R&D, Unilever Wellbeing. 'What we developed was an amino acid blend available in our Sugar-Free Hydration Multiplier, all delivered within a delightful peach flavoured beverage.' Liquid I.V. Sugar-Free White Peach Hydration Multiplier delivers smart 0 sugar hydration that supports consumers in maintaining their wellness goals. It contains: 0g sugar 6 essential vitamins and minerals Blend of amino acids No artificial flavours or colours 100% + daily value of essential B vitamins (B3, B5, B12) To enjoy, simply pour one easy-to-open packet into 500ml of water, mix or shake, and hydrate. Its convenient single-serve, travel-friendly packets are easy to enjoy on the go. Liquid I.V. Sugar-Free White Peach is currently available at Costco Canada and will be available on later this month. About Liquid I.V.® Liquid I.V.® is a wellness company based in Los Angeles, CA. We believe hydration is the bedrock of wellness so our products are designed to deliver hydration and additional benefits with delicious flavour. The product line features great-tasting, non-GMO electrolyte drink mixes for enhanced hydration. As a purpose-driven brand, giving back is at the core of Liquid I.V.'s DNA, to date we've donated over 71 million servings to people in need around the globe. Liquid I.V.® contributes over 1% of brand revenue to our Impact Program focused on Clean Water Access & Hydration Aid. Liquid I.V.® provides grants to organizations that expand clean water access. We are committed to our goal of donating 150 million Liquid I.V.® sticks over the next 10 years. Liquid I.V. is available in-store at Costco, Walmart, and other national retailers, and online on To learn more, visit and follow @liquidivcanada on Instagram, TikTok and Facebook. For more information, please contact:Amanda FederchukKetchum, on behalf of Liquid I.V. [email protected] 416-505-0517
